Design and Evaluation of Gastro-Retentive Floating Tablets of Etidronate disodium

Osteoporosis raises the chance of breaking a bone strength. It is the most frequent cause of fractures in the elderly. The hip, forearm, and back bones are among the bones that break most frequently. Usually, there are no symptoms until a broken bone happens. In order to target site-specific drug release in the upper GIT for a local or systemic effect, GRDDs are a method of extending the gastric residence time. For a very long time, gastro retentive dosage forms (GRDFs) have been used to enhance treatment with a number of significant medications. Paget's disease is a particular kind of bone disease that is treated with etidronate disodium.Bones are weakened and deformed by this disease. To improve its oral bioavailability, etidronate disodium, the most widely used biphosphonate for osteoporosis treatment, was made into gastro retentive dosage form (GRDF) tablets. Carbopol 934P, HPMC 4KM, and Na-CMC at different ratios were used to characterize the effects of GRDF tablets of Etidronate disodium (200 mg) on swelling, floating, and physical integrity. The thickness, friability, hardness, drug content, and in-vitro drug release of the Risedronate GRDF tablets produced in this study were all found to have a prolonged dissolution profile. Oral drug delivery is still the most popular method despite significant advancements in the field because it is simple to administer, therapy is inexpensive, and patient compliance is high. Keywords: Gastro retention, Etidronate disodium, Carbopol 934P, HPMC 4KM, Na-CMC, GRDF, GRFT.